In an announcement by the National Institute for Health and Care Excellence (NICE) it confirms that Zilucoplan (Zilbrysq) ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR ...

Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...

Background Myasthenia gravis (MG) represents a heterogeneous group of autoantibody-mediated diseases targeting the neuromuscular junction. Extraocular muscles (EOMs) are highly susceptible to ...

Myasthenia Gravis (MG) is an autoimmune neuromuscular disease. Given that extraocular muscle manifestations are the initial and primary symptoms in most patients, ocular muscle assessment is regarded ...

Vor Bio is licensing global rights to a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last ...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published ...

Myasthenia gravis (MG) is an autoantibody disease in which the immune system mistakenly makes antibodies (e.g., anti-acetylcholine receptor [AChR], anti-muscle-specific tyrosine kinase [MuSK ...

Initial disease manifestations are usually eye-related but approximately 85% of MG patients experience additional advancements to the disease manifestations—referred to as generalised myasthenia ...